Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now
- PMID: 31714261
- DOI: 10.1097/COH.0000000000000602
Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now
References
-
- Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
-
- Celum C, Baeten JM. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and preexposure prophylaxis. Antivir Ther 2012; 17:1483–1493.
-
- Celum C, Baeten JM. Tenofovir-based preexposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 2012; 25:51–57.
-
- Gandhi M, Glidden DV, Liu A, et al. Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: implications for preexposure prophylaxis adherence monitoring. J Infect Dis 2015; 212:1402–1406.
-
- Grant RM, Anderson PL, McMahan V, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820–829.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
